SCHEMBL5010227

SCHEMBL5010227

FC1[C]Oc2ccccc2O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1038844 0.73
SCHEMBL442812 0.73
SCHEMBL438270 0.73 POLB (0.33)
SCHEMBL1898922 0.71
SCHEMBL10515359 0.69 ABCG2 (0.36)
SCHEMBL452883 0.68
SCHEMBL4413227 0.68 POLB (0.31)
SCHEMBL5326093 0.68 MAOA (0.37)
SCHEMBL11227302 0.64 MAOA (0.33)
SCHEMBL3072276 0.64 MAOA (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492431-B2 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity JANSSEN PHARMACEUTICA, N.V. (BE) 2013-07-23 US claimed
EP-1968573-A2 USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER Janssen Pharmaceutica, N.V. (BE) 2008-09-17 EP claimed
WO-2007075695-A2 USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-05 WO claimed